Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 66,583 |
|
|||||
| News | - | ||||||
| Day High | 1.04 | Low High |
|||||
| Day Low | 0.99 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Talphera Inc | TLPH | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.02 | 15:30:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.03 | 0.99 | 1.04 | 1.02 | 1.02 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 253 | 66,583 | US$ 1.03 | US$ 68,275 | - | 0.72 - 1.61 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:20:33 | 1 | US$ 1.04 | USD |
Talphera Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 17.48M | 16.97M | - | 651k | -18.4M | -1.08 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Talphera News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TLPH Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.08 | 1.10 | 0.9734 | 1.01 | 44,530 | -0.06 | -5.56% |
| 1 Month | 1.12 | 1.24 | 0.92 | 1.08 | 72,199 | -0.10 | -8.93% |
| 3 Months | 0.84 | 1.61 | 0.84 | 1.17 | 98,117 | 0.18 | 21.43% |
| 6 Months | 0.86 | 1.61 | 0.72 | 1.10 | 113,518 | 0.16 | 18.60% |
| 1 Year | 0.86 | 1.61 | 0.72 | 1.10 | 113,518 | 0.16 | 18.60% |
| 3 Years | 0.86 | 1.61 | 0.72 | 1.10 | 113,518 | 0.16 | 18.60% |
| 5 Years | 0.86 | 1.61 | 0.72 | 1.10 | 113,518 | 0.16 | 18.60% |
Talphera Description
| AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. |
